Topical Autologous Platelet-Rich Plasma Eyedrops for Acute Corneal Chemical Injury

Abstract

Topical autologous platelet-rich plasma therapy is safe and effective, and it promotes rapid reepithelialization of ocular surface and can be administered along with standard medical therapy.

Chemical Injury-Induced Corneal Opacity and Neovascularization Reduced by Rapamycin via TGF-β1/ERK Pathways Regulation

“…The effectiveness of several drugs for the treatment of chemical burn-induced corneal NV and opacity has been investigated. [2][3][4] Nevertheless, the clinically prescribed drugs have not been effective as prophylactic treatments to prevent corneal NV and opacity development. The role of vascular endothelial growth factors (VEGF) in corneal chemical burn has been investigated in previous studies.…”

Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

“…In addition, there have been few reports that show the efficacy of some blood products such as platelet-rich plasma (PRP) in treating chemical burns [32, 49]. Hence, we started using AS eye drops for different ocular surface diseases that were not responding to conventional therapies.…”

“…Few studies are available in the literature on chemical burns, and used as a treatment PRP [32], umbilical cord serum [33], or amniotic membranes [59]. Corneal chemical burns cause corneal infection, ulceration, opacity, and neovascularization.…”

“…Since its introduction, this treatment has become increasingly popular and the indications for its use have expanded rapidly [9]. To date, AS is used for the treatment of persistent epithelial defects [10–15], dry eyes [1, 8, 16–27], neurotrophic keratopathy [28], recurrent erosion syndrome [29, 30], superior limbic keratoconjunctivitis [31], and chemical injuries [32, 33]. …”

Untitled

“…The bioactive proteins include Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Epidermal Growth Factor (EGF), Fibroblast Growth Factors (FGF) and Insulin-like Growth Factor-1 (IGF-1), as well as cytokines, such as Platelet Factor 4 (PF4) and Cluster of Differentiation 40 Ligand (CD40L) [65][66][67]. Platelet-Rich Plasma (PRP) has been used to treat acute corneal chemical injury [68], severe dry eye [69], dormant ulcers [70], including neurotrophic, exposure and limbal deficiency with corneal ulcer after herpetic keratitis, and three case reports of corneal ulcer which included neurotrophic ulcer, exposure corneal ulcer, and limbal deficiency with corneal ulcer after herpetic keratitis [71]. Selected components of tears, serum and PRP are compared in table 2 [72,73].…”